Asploro Journal of Biomedical and Clinical Case Reports · May 18, 2026
Improvement of HbA1c and LDL-C by Imeglimin (Twymeeg) in the Diabetic Female Elderly
By Bando H, Ogawa T, Iwatsuki N et al.
The case is a 77-year-old female who was treated for arteriosclerosis and gastroesophageal reflux disease (GERD). In March 2025, type 2 diabetes (T2D) was detected, with HbA1c of 8.8%. Physical examination was negative, with BMI of 21.7 kg/m². Blood chemistry examination revealed LDL of 142 mg/dL, and pulse wave velocity (PWV) showed a cardio-ankle vascular index (CAVI) of 9.9/9.6 and ankle-brachial index (ABI) of 1.11/1.07. She was advised to follow a petite low-carbohydrate diet (LCD), treated with imeglimin (Twymeeg), and subsequently received rosuvastatin, vildagliptin, and metformin. As a result, she showed improvement, with HbA1c of 7.0% and LDL of 78 mg/dL in March 2026, indicating remarkable clinical efficacy.